A Dual-Mechanism Based Nutrient Partitioning Nanoregulator for Enhanced Immunotherapy against Anti-PD-1 Resistant Tumors

被引:15
|
作者
Zhang, Ruirui [1 ]
Li, Ruifang [1 ]
Zhang, Lan [1 ]
Chen, Ge [1 ]
Mo, Lianfeng [1 ]
Jiang, Ru [2 ]
Xu, Xiaoxia [2 ]
Wang, Xueqin [1 ]
Zhao, Yingyuan [1 ]
Zhang, Lianzhong [2 ]
Wang, Yongchao [3 ]
Zhang, Beibei [1 ,2 ]
机构
[1] Henan Univ Technol, Sch Biol Engn, Zhengzhou 450001, Peoples R China
[2] Henan Univ, Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Ultrasound,Peoples Hosp, Zhengzhou 450003, Peoples R China
[3] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
nanoregulator; nutrient partitioning; immunosuppressiveTME; immunotherapy; anti-PD-1 resistant tumor; CANCER; BIODEGRADABILITY; NANOPARTICLES; METABOLISM; GLUCOSE;
D O I
10.1021/acsnano.3c01743
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Competitive consumption of nutrients between rapidlyproliferatingcancer cells and T cells results in an immunosuppressive tumor microenvironment(TME) and nutrient deprivation of T cells, which can cause low responserate and resistance to immunotherapies. In this study, we proposeda dual-mechanism based nutrient partitioning nanoregulator (designatedas DMNPN), which can simultaneously regulate the immunosuppressiveTME and enhance T cell nutrient availability. DMNPN consists of acharge-reversal biodegradable mesoporous silica, encapsulating glycolysisinhibitor lonidamine, and small interfering RNA against glutaminase.Through inhibiting glycolysis to decrease the lactic acid productionand downregulating glutaminase expression to reduce the uptake ofglutamine by tumor cells, DMNPN enables effective remodeling of metabolismand nutrient partitioning, which alleviates the immunosuppressiveTME and boosts nutrient availability for T cells with enhanced antitumorimmunity. Such a nutrient partitioning nanoregulator can effectivelyinhibit the growth of anti-programmed death receptor 1 (anti-PD-1)resistant tumors and prevent tumor metastasis and recurrence. Overall,this dual-mechanism based nutrient reallocation strategy providesa promising approach for cancer therapy.
引用
收藏
页码:13461 / 13473
页数:13
相关论文
共 50 条
  • [31] Phase 2 Study of NP-G2-044, a Novel Fascin Inhibitor, in Combination with Anti-PD-1 Therapy in Patients with Solid Tumors Resistant to Prior Anti-PD-1 Therapy
    Kasi, Anup
    Birrer, Michael
    Brown, Jason
    Chandrasekaran, Sanjay
    Chung, Vincent
    Frank, Richard
    Gadgeel, Shirish
    George, Thomas
    Jalal, Shadia
    Mendivil, Alberto
    Poklepovic, Andrew
    Segar, Jennifer
    Spira, Alexander
    Tanyi, Janos
    Zhang, Jillian
    Huang, Xin-Yun
    Jimeno, Jose
    Tsai, Frank V.
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [32] Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma
    Gao, Yaru
    Huo, Yue
    Wang, Lingli
    Ruan, Jiayi
    Chen, Lanzhen
    Li, Hongdong
    Hong, Guini
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [33] An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma
    Yang, Lin
    Zhao, Qiuling
    Liu, Wenbin
    Chen, Ting
    Qiu, Xiuliang
    Chen, Jincan
    Huang, Shengqiang
    Huang, Ruyi
    Dong, Liangliang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3767 - 3780
  • [34] An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
    Lin Yang
    Qiuling Zhao
    Ting Chen
    Wenbin Liu
    Xiuliang Qiu
    Jincan Chen
    Shengqiang Huang
    Ruyi Huang
    Liangliang Dong
    Clinical and Experimental Medicine, 2023, 23 : 3767 - 3780
  • [35] Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies
    Azpilikueta, Arantza
    Agorreta, Jackeline
    Labiano, Sara
    Luis Perez-Gracia, Jose
    Sanchez-Paulete, Alfonso R.
    Angela Aznar, M.
    Ajona, Daniel
    Gil-Bazo, Ignacio
    Larrayoz, Marta
    Teijeira, Alvaro
    Rodriguez-Ruiz, Maria E.
    Pio, Ruben
    Montuenga, Luis M.
    Melero, Ignacio
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 524 - 536
  • [36] A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy
    Liu, Yingqiang
    Tong, Linjiang
    Zhang, Mengge
    Zhang, Qi
    Liu, Qiupei
    Feng, Fang
    Li, Yan
    Lai, Mengzhen
    Tang, Haotian
    Chen, Yi
    Geng, Meiyu
    Duan, Wenhu
    Ding, Jian
    Xie, Hua
    CANCER COMMUNICATIONS, 2024, 44 (03) : 438 - 442
  • [37] Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase
    Valero, Cristina
    Lee, Mark
    Hoen, Douglas
    Zehir, Ahmet
    Berger, Michael F.
    Seshan, Venkatraman E.
    Chan, Timothy A.
    Morris, Luc G. T.
    JAMA ONCOLOGY, 2021, 7 (05) : 739 - 743
  • [38] Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors
    Moerk, S. K.
    Donia, M.
    Kringelum, J. V.
    Bogenrieder, T.
    Rono, B.
    Sorensen, A. B.
    Draghi, A.
    Bol, K. F.
    Petersen, N. V.
    Kadivar, M.
    Hernandez, S. S.
    Hadrup, S. Reker
    Andreasen, L. V.
    Christensen, D.
    Andersen, P. L.
    Svane, I. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 41 - 41
  • [39] Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma
    Kim, Tae Woo
    Kim, Yujin
    Keum, Hyeongseop
    Jung, Wonsik
    Kang, Minho
    Jon, Sangyong
    MOLECULAR THERAPY-ONCOLYTICS, 2022, 26 : 1 - 14
  • [40] Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy
    Tremblay, Marie-Laurence
    O'Brien-Moran, Zoe
    Rioux, James A.
    Nuschke, Andrea
    Davis, Christa
    Kast, W. Martin
    Weir, Genevieve
    Stanford, Marianne
    Brewer, Kimberly D.
    ONCOIMMUNOLOGY, 2020, 9 (01):